Tirzepatide for Weight Loss Cost in New York

Tirzepatide for Weight Loss in New York costs $278 to $1,445 in 2026, with a state-wide median of $472. Pricing varies by metro - typically $561 in New York and $446 in Albany. New York pricing is 11% above the national average.

Syracuse typically has the lowest tirzepatide for weight loss pricing in New York, with a median of $395 (0.93x national average). Mid-size markets generally run lower than major coastal or wealthy suburban areas.

New York typically has the highest tirzepatide for weight loss pricing in New York, with a median of $561 (1.32x national average). Larger metro areas with higher cost of living and more specialty providers tend to command premium pricing.

Zepbound is covered by some commercial insurance plans with prior authorization, though coverage is less broad than semaglutide. Medicare does not cover Zepbound for obesity. Many employers exclude obesity medications from formularies.

New York pricing is 11% above the national average. The state cost index is 1.11x the national average. Higher-cost states include California, New York, Massachusetts, and Washington DC; lower-cost states include Oklahoma, Mississippi, Kentucky, and Indiana.

Brand-name Zepbound retails at approximately $1,000 to $1,300 per month without insurance in 2026. Compounded tirzepatide from licensed 503A pharmacies through telehealth weight-loss clinics typically runs $250 to $600 per month. With insurance coverage for Zepbound, out-of-pocket can be $25 to $100 monthly with prior authorization. Medicare does not cover for obesity but does cover Mounjaro for type 2 diabetes.

Yes, in head-to-head and indirect trial comparisons, tirzepatide delivers slightly greater average weight loss: 18-22 percent at 72 weeks (SURMOUNT-1) versus 12-17 percent at 68 weeks for semaglutide (STEP 1). The difference is roughly 4-6 percentage points of body weight. The SURPASS-2 trial directly compared the two in type 2 diabetes and found tirzepatide superior on weight loss and A1c reduction.

Both contain the same active molecule (tirzepatide). Zepbound is FDA-approved for chronic weight management at doses up to 15 mg/week. Mounjaro is FDA-approved for type 2 diabetes at doses up to 15 mg/week. The medications are functionally identical; the brand split is for indication-specific marketing and insurance formulary purposes.

Published clinical trials show average weight loss of 18-22 percent of starting body weight at 72 weeks on the maximum dose (15 mg/week). For a 220-pound starting weight, that is approximately 40-48 pounds. About 90 percent of patients achieve at least 5 percent weight loss; about 50 percent achieve at least 20 percent.

Compounded tirzepatide from licensed 503A pharmacies using FDA-approved API is widely considered safe by clinicians, though it carries less manufacturing oversight than brand-name Zepbound. Risks include variable potency, contamination, and use of unapproved salt forms by lower-quality compounders. Following the FDA resolution of the tirzepatide shortage in October 2024, compounding pathways have tightened. Verify your clinic uses an FDA-registered 503A pharmacy with FDA-approved API.